Ian Johnson
Biomedical
Ian has spent his business career in life science. He was founder and CEO of Biotrace International plc, a listed company in which Harwood was a major holder of shares until its sale to 3M in December 2006. Ian was non-executive chairman of two investments of Harwood Private Equity: Celsis Group (a public-to-private investment); and Cyprotex plc (a PIPE expansion-capital investment).
Ian studied at University College Cardiff obtaining an M.Sc. by thesis in Microbiology. He is a chartered biologist, a member of the Institute of Biology and of the Institute of Directors, as well as being the author of numerous publications and patents in the field of rapid microbiological testing.
